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Abstract
Tardive dyskinesia remains an elusive and significant clinical entity that can possibly be understood via
experimentation with animal models. We conducted a literature review on tardive dyskinesia modeling. Subchronic
antipsychotic drug exposure is a standard approach to model tardive dyskinesia in rodents. Vacuous chewing
movements constitute the most common pattern of expression of purposeless oral movements and represent an
impermanent response, with individual and strain susceptibility differences. Transgenic mice are also used to
address the contribution of adaptive and maladaptive signals induced during antipsychotic drug exposure. An
emphasis on non-human primate modeling is proposed, and past experimental observations reviewed in various
monkey species. Rodent and primate models are complementary, but the non-human primate model appears
more convincingly similar to the human condition and better suited to address therapeutic issues against tardive
dyskinesia.
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Introduction
Tardive dyskinesia (TD) is a disabling and potentially
irreversible motor complication encompassing all persis-
tent, abnormal, involuntary hyperkinetic movements
occurring in the setting of chronic therapy with dopa-
mine receptor-blocking agents, such as antipsychotic
drugs and metoclopramide [1]. The resulting movement
disorder is most often stereotyped in nature and typi-
cally involves the orobuccolingual musculature. As TD
remains an elusive drug complication over 50 years
since its initial description, it is not surprising that the
treatment options available are non-specific and produce
mixed results.
Unfortunately, the early hope that second-generation
(so-called atypical) antipsychotic drugs would afford a
gradual disappearance of TD has been challenged by
recent reports that one third of patients chronically
exposed to antipsychotic drugs still develop TD [2-4].
The annual risk remains greater in older adults, particu-
larly in those living with a dementing illness [5]. Severe
forms of TD also develop with the new antipsychotic
drugs [6]. The persistence of TD in the community, and
the enlarging spectrum of conditions for which antipsy-
chotic drugs are prescribed (e.g., bipolar disorder, refrac-
tory depression), make it urgent to develop a better
understanding of this hyperkinetic movement disorder,
as well as novel preventive and palliative approaches.
The use of animal models is inescapable and irreplace-
able in reaching that goal. The advances made since the
levodopa-induced dyskinesia primate model was intro-
duced in neuroscience 25 years ago well illustrate that
point [7,8]. Before mechanistic considerations are
addressed, any experimental movement disorder model
must first reproduce the phenomenology of the human
condition, a test the levodopa-induced dyskinesia pri-
mate model has unequivocally passed. The purposeless
hyperkinetic movements should be reproducible, quanti-
fiable, and easily distinguishable from normal move-
ments. This personal review of rodent as well as non-
human primate TD models provides an opportunity to
reflect upon the diversity of protocols, and lack of con-
sensus thereof, and to suggest the most fruitful
approaches. Cats and guinea pigs have rarely been used.
We also take advantage of this exercise to compare the
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non-human primate modeling.
Rat models
The use of rats exposed to antipsychotic drugs for con-
secutive weeks has been proposed with variations since
the early 70’s. Originally, brief exposure of guinea pigs
to chlorpromazine was followed by abrupt withdrawal
and challenge with dopamine receptor agonists, which
triggered stereotyped gnawing and sniffing [9]. The
rapid onset of the motor stereotypies and need to
sequentially use dopamine antagonist and agonist drugs
certainly do not replicate the delayed course and sponta-
neous occurrence of TD in humans treated with dopa-
mine receptor-blocking agents. Many laboratories have
then characterized the spontaneous oral movements
emerging during subchronic or chronic antipsychotic
drug administration. The behavioural results obtained
have been summarized in authoritative literature reviews
[10,11], which documented different patterns and
descriptors of oral movements, most commonly
reported as robust, seemingly purposeless, chewing
activity (so-called vacuous chewing movements or
VCM), often fluctuating and occurring in short bursts,
occasionally associated with bruxism and tongue protru-
sions. Rapid wide mouth openings and bursts of oro-
mandibular tremor or twitching may be distinguished.
In most reports, the proportion of animals displaying
high VCM scores range from 30% to 50% according to
the type of antipsychotic used, as well as the route of
drug administration [11-18].
The VCMs and tongue protrusions are typically
counted during repeated 2- to 5-min session blocks in
an observation cage equipped with a mirror placed in
the back to improve visibility, after a variable habitua-
tion period to the new environment (up to 1 h), in sin-
gle freely moving animals without access to food. Other
investigators prefer to use stopwatches to record burst
duration rather than single events. An observation tube,
restraining the animal placed in front of a camera
focused on the head, has been tested to optimize motor
assessment, but requires much longer habituation to
reduce stress effects [19]. This can be combined with a
computer-assisted detection system to measure oral
movements that cannot be visually quantified, but does
not obviate the need for visual examination to distin-
guish purposeless chewing from bursts of jaw tremor or
behavioural stereotypies temporally related to grooming
or gnawing. Although drug-induced hypoactivity of the
animal in the cage may facilitate and bias VCM detec-
tion, no significant change in locomotion was documen-
ted between VCM and VCM-free rats in one study, and
grooming behaviour was not considered a hindrance to
VCM counting [20]. In contrast to human TD, extraoral
dyskinesia has not been observed.
It is important but complex to distinguish early-onset
from gradual late-onset VCMs in rodents during expo-
sure to antipsychotic drugs. Early VCMs emerge rapidly
(1-21 days), are sensitive to anticholinergic drugs, and
may more closely reflect acute extrapyramidal symptoms
(EPS) (parkinsonian tremor, dystonia), whereas more
delayed VCMs (> 3 months) are insensitive to anticholi-
nergics, and may better reflect tardive dyskinesia
[10,12,21]. These two patterns are also associated with
differences in neuropeptide gene expression in the stria-
tum [21]. Thus, although similar from a behavioural
perspective, early- and late-onset VCMs appear to have
different pharmacological and neurochemical profiles.
Unfortunately, the transitional time point between early-
and late-onset VCMs remains elusive. It is suggested
that rats with late-onset high-VCM drug responses
should be included in TD studies. In contrast to brief
drug exposure protocols, long-term exposure seems
more likely to promote the persistence of the VCM
response following drug withdrawal, typically vanishing
over a 2-week follow-up period [22], although longer
persistence for several months has been documented
[10,23].
In contrast to levodopa-induced dyskinesia, continu-
ous administration using depot formulations (e.g., halo-
peridol decanoate i.m.) produces a stronger VCM
response compared to daily, dose-equivalent (i.p.), inter-
mittent drug administration [11]. The importance of
this observation is exemplified by the fact that continu-
ous, but not intermittent, antipsychotic drug administra-
tion, delivered through a subcutaneous osmotic
minipump, has generated high VCM scores, in spite of
similar total daily doses [24,25]. Continuous levels of
dopamine D2 receptor occupancy during antipsychotic
drug exposure increase the risk of receptor upregulation
[26,27], and could trigger distinct drug-induced neuroa-
daptation. Indeed, continuous, but not intermittent,
haloperidol administration exacerbates psychostimulant
drug reward behaviours and is associated with an aber-
rant psychostimulant-induced striatal gene regulation
[28].
Since long-term drug exposure is not cost- and time-
efficient, several laboratories still use a 3-week drug pro-
tocol to generate a VCM response, while others have
attempted to find ways to accelerate and magnify rat
TD-like oral activity with less variability. Old rats have
been tested. Indeed, advancing age is the single most
significant risk factor for early TD induction and persis-
tence [29-31]. Old rats generally show a reduced level of
spontaneous motor activity, but a higher level of oral
movements in the unmedicated state, compared to
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may show a stable (ceiling effect) or heightened VCM
response. It is unclear whether the use of aged rats pro-
vides a distinct advantage in experimental TD protocols
[14,32,33]. Of practical importance in study design, cer-
tain strains such as the Long-Evans rats display a more
robust VCM response in all treated individuals, whereas
38% of Sprague-Dawley rats never express VCM over 24
weeks [34]. Unlike in the human literature, the impact
of gender and diabetes on experimental TD has been lit-
tle addressed. One study reported a heightened VCM
response in female mice that was inconsistent at differ-
ent time points [35]. The influence of glucose metabo-
lism on the VCM induction process and severity has not
been investigated, but a surprising apparent reduction in
apomorphine-enhanced VCM has been observed in dia-
betic rats exposed to haloperidol compared to control
rats [36]. A few attempts to enhance the susceptibility
to TD in rats with pre-existing central nervous system
injury have been published [37,38]. While unnatural and
remote from the experience of most people developing
TD, these experiments may still provide clues about TD
induction. Frontal cortex lesions generated more severe
and persistent abnormal oral behaviours in adult rats
after antipsychotic drug withdrawal [37], and neonatal
dopamine denervation with 6-hydroxydopamine had an
even greater impact on the severity of the VCM
response triggered by haloperidol, which persisted for 8
months following drug withdrawal [38]. Partial dopa-
mine loss may thus constitute a sensitization stage prior
to the precipitation stage resulting from drug exposure,
but whether this has some bearing on the vulnerability
to TD seen in normal aging is undetermined. The sensi-
tization stage may trigger additional pathogenic mechan-
isms contributing to the drug-induced neural changes
conducive to TD, such as the sensitivity of dopamine D1
and serotonin 5-HT2C receptors [38], and/or lessening
the endogenous adaptive response mounted to fend off
TD.
One finding raising concern about the relevance of the
VCM response is the apparent similar behaviour pro-
duced by the acute (3 days) or chronic (4-6 weeks)
administration of the presynaptic monoamine depleter
reserpine. This drug can trigger VCM, tongue protru-
sions, and facial twitching, which persist for periods
extending up to 2 months following drug withdrawal
[39]. These oral movements were more persistent in old
than in young animals following drug withdrawal [32].
No general consensus exists concerning the validity of
the reserpine model.
Thus, chronic antipsychotic drug exposure (typically
with haloperidol) for at least 3-4 months appears to
represent a standard approach to model TD in rats. The
VCM response certainly does not display the complexity
of human TD, and may appear very early in some ani-
mals during drug exposure. The model still provides
insights about the human disorder, and has been pro-
posed in experiments using antisense oligonucleotides to
knockdown site-directed single target proteins that may
be closely associated with the VCM response. For
instance, intrastriatal infusion of oligonucleotide anti-
s e n s et od o p a m i n eD 1A receptor mRNA has selectively
reduced receptor binding and VCMs in rats exposed to
fluphenazine decanoate [40].
It is well established that haloperidol and other typical
antipsychotic drugs (D2 receptor antagonists) upregulate
dopamine D2 receptors. This led to the suggestion that
late-onset dyskinesia was a reflection of dopamine
receptor supersensitivity [9]. However, several observa-
tions indicate that D2 receptor upregulation alone is not
sufficient to account for TD. In rats, haloperidol-
induced D2 receptor upregulation develops early during
treatment (within 15 days), while tardive VCMs only
develop after much prolonged treatment [41,42].
Furthermore, D2 receptor upregulation similarly occurs
in haloperidol-treated rats showing no or low VCMs
and those displaying high VCM scores [11]. Similarly,
no difference in striatal D2 receptor binding has been
observed in patients with TD compared to antipsychotic
drug-treated patients without TD [43].
Morphological changes observed in rats exposed to
antipsychotics with high VCM scores included altera-
tions in striatal synaptic morphology [15,18], medial
substantia nigra pars compacta nerve cell loss and atro-
phy particularly in aged rats [14], and alterations in
nucleus accumbens dendritic spine density [16], but
decreased spine density was not associated with VCM in
the striatum [17]. Reductions in striatal choline acetyl-
transferase activity [44,45] and in the number of large
striatal (presumably cholinergic) interneurons [45,46]
have been reported following chronic antipsychotic drug
exposure in rats, but the relevance of the results to TD
and distinction from age-related effects remain unclear.
Neurochemical data seem to point out to an important
role of striatal dynorphin expression and/or increased
glutamatergic activity [13,15,16,18,21]. However, the lat-
ter observations are correlative in nature, and no study
designed to evaluate a causal link between these changes
and induction of high VCM scores has been conducted
so far.
Transgenic mouse models
Transgenic mice consist of strains whose genetic mate-
rial has been deliberately modified using foreign DNA
transfer into the host embryo by recombinant DNA
technology. They are used to study the contribution of
knockout genes on the response to antipsychotic drugs
and on motor complications in particular. In the past,
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striatal gene and protein expression following the
administration of different antipsychotic drugs [47,48].
We have examined Nur77 knockout mice and character-
ized their VCM response following the administration of
haloperidol for up to 17 weeks [49]. Nur77 (NGFI-B,
NR4A1) is a transcription factor of the nuclear receptor
family expressed in dopaminoceptive circuits, whose
striatal expression is upregulated by haloperidol in stria-
topallidal neurons [50,51]. Interestingly, Nur77 knockout
mice display spontaneous VCMs in the unmedicated
state and a stronger VCM response following haloperi-
dol exposure compared to wild type mice (see accompa-
nied Additional file 1: Table S1) [49]. This suggests that
neurochemical changes induced by genetic deletion of
Nur77 might have recapitulated some susceptibility pro-
cesses observed in humans with TD. We also showed
that a single nucleotide polymorphism (SNP, rs2603751)
located in the 3’-UTR (untranslated regulatory region)
of the Nur77 mRNA displayed a nominal association
with the risk of developing TD, as well as with TD
intensity based on Abnormal Involuntary Movement
Scale (AIMS) scores in a group of schizophrenia patients
[52]. More studies are underway to shed light on the
signalling partners and cellular effects of this nuclear
receptor in the basal ganglia, in normal and drug-
primed conditions.
Non-human primate model
The initial attempts to model TD in macaques were not
encouraging, with impermanent dyskinetic signs often
admixed with acute dystonic reactions [54,55]. For these
reasons, this TD model has been underused compared
to the levodopa-induced dyskinesia primate model,
explaining in part the existing gap in knowledge
between the two iatrogenic disorders. With careful anti-
psychotic drug exposure, the abnormal movements
observed are similar to those found in humans and typi-
cally stereotyped in nature, without concomitant acute
dystonic reaction or interference with food intake and
well-being (see accompanied Additional file 1: Table
S1). Variable orofacial dyskinetic movements are seen (6
of 7 TD capuchins in our laboratory), including fore-
head contractions, chewing movements, tongue protru-
sions, and lip retraction (Figure 1). Neck rotation, brief
back extension, and flexion/extension movements of the
toes, are also seen. Upper limb chorea was occasionally
observed. In some reports, the abnormal movements
have persisted for several months following drug
withdrawal.
Although the review of 21 published studies suggests
marked interspecies differences in susceptibility that
should be interpreted with caution in view of the var-
ious drug protocols used (see Additional file 2), the TD
rate in primates is favourable and exceeds the annual
incidence of 3-5% generally reported in human adults
[74]. A cumulative account of the original experiments
that have used Macaca species indicates that only 8%
(10/122) of the subjects chronically exposed to antipsy-
chotic drugs alone developed TD. The mean (± SD)
drug exposure of 14.1 (± 14.8) months was somewhat
shorter than in capuchins. Baboons do not tolerate halo-
peridol well, and it is unknown whether they may safely
be exposed to other first-generation antipsychotic drugs.
Nonetheless, the dehydrated derivative of haloperidol, 4-
(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-
1,2,3,6-tetrahydropyridine (HPTP), was chronically
administered with success to these animals and rapidly
triggered TD [64]. In three New World monkey species,
squirrels (Saimiri sciureus), capuchins (Cebus apella)
and marmosets (Callithrix jacchus), TD developed in
proportions of 0% (0/5 animals in a single study), 45%
(32/71, including 7/18 observed in our laboratory) and
71% (12/17 in two studies), respectively. The onset of
TD is unpredictable and highly variable in capuchins as
well as in marmosets, with a mean latency of onset of
33.4 (± 22.9) months and 18.0 (± 8.5) months, respec-
tively. In our 7 TD capuchins, the mean latency of onset
was 17 months (median, 10 months; range 3-35
months). Interestingly, capuchins carry the gly9 poly-
morphism in the dopamine D3 receptor gene [75] that
has been associated with TD in humans [76]. This
genetic trait has not been sought in marmosets. The dif-
ferential susceptibility of various non-human primate
species to TD is reminiscent of the variable prevalence
in TD reported in humans of diverse ethnic background,
a very complex issue lacking conclusive evidence at pre-
sent [77].
In the drug protocols examined (Additional file 2),
haloperidol and fluphenazine were most often used and
the duration of exposure generally extended to at least
one year. Chronic oral drug administration was slightly
more effective at triggering TD in capuchins than depot
i.m. preparations, with incidence of 53% and 42%,
respectively, but the cumulative drug exposure resulting
from these two drug regimens may well have differed.
On the other hand, in common marmosets exposed to
haloperidol [72,73], a depot i.m. preparation more effec-
tively triggered TD than oral administration, a result
which could be in line with the rat data discussed pre-
viously. Although the interrupted or sustained nature of
the drug protocols pursued did not appear to correlate
with TD susceptibility, temporary drug suspension did
trigger persistent withdrawal-emergent TD in some ani-
mals [78,61], including 3 of our 18 capuchin monkeys.
Thus, it appears reasonable to suspend drug exposure
from time to time, at least to ensure that TD is not
masked by parkinsonian features.
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human primates [62,72]. We have used a primate
equivalent of the Abnormal Involuntary Movements
Scale (AIMS) to blindly score body segments (orofacial
[forehead, lips, tongue, jaw], neck, trunk, and each limb)
between 0-4 points (absent to severe intensity), for a
maximum score of 40 points. The intensity of TD in
our animals was generally mild, and orofacial scores
accounted for approximately 40% of the total TD score.
As reported previously [61], stress enhances TD and
should be kept constant as much as possible. Reminis-
cent of the diurnal variability in orofacial TD measured
in a fraction of TD patients [79], TD intensity showed
some variability in the short term (Figure 2), and the
spontaneous dispersion of TD ratings (N = 6) in 3 data
sets of normal distribution generated 4 weeks apart
revealed a mean coefficient of variation of 31.5% (range
10.2-49.5). We calculated that a sample size of 7
Figure 1 Seven capuchins displaying tardive dyskinetic movements causing variable tongue protrusions, as well as forehead
contractions, lip retraction, and neck twisting.
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dyskinetic properties of an investigational drug, taking
into account the spontaneous variability in TD scores,
and a power of 80% and alpha value of 0.05 to detect an
antidyskinetic effect size of at least 50% relative to base-
line scores.
Although the TD incidence in capuchin monkeys
exceeds several-fold that in humans and macaques, the
unpredictability, long delay of induction, and cost of this
experimental TD model, constitute impediments to
broad applications. As in the rodent model, certain fac-
tors have been proposed to accelerate experimental TD
induction. High drug dosing may seem desirable to sen-
sitize basal ganglia circuits and promote TD induction
(Additional file 2), but this often triggers acute dystonic
reactions even during maintenance of drug exposure
[80]. Thus, we have elected to administer low i.m.
weekly doses. Such dosing frequency could better
account for the faster metabolism and clearance of halo-
peridol reported in non-human primates compared to
humans [81]. It is unknown whether antipsychotic drug
disposal in rhesus is faster than in capuchins, but this
could in part explain their apparent low TD susceptibil-
ity. As in rats, acute drug challenge with a dopamine
agonist has been proposed in monkeys as a way to
reflect the behavioural sensitivity of animals chronically
exposed to antipsychotic drugs and enhance experimen-
tal TD, but the impact of this strategy wanes over time
and its validity as a model has been questioned [82].
T h ea g eo ft h ea n i m a l sh a sb e e nl i t t l ee x a m i n e d[ 6 1 ] .
Since the availability of monkeys over 24 years of age is
limited, this strategy is not widely applicable. Bilateral
ovariectomy was first performed in our females to
reduce gonadal hormone modulation on brain dopamine
and GABA receptors during the estrous cycle [83-86], as
proposed in the levodopa-induced dyskinesia primate
model [87]. Although it is intuitively beneficial to repro-
duce the postmenopausal hormonal status of women
most at risk for TD [88], this procedure does not make
a senescent brain and its place as a TD-enhancing strat-
egy remains undetermined. The use of common marmo-
sets has also been suggested since they tend to display
TD sooner (see Additional file 2), often within the first
year after antipsychotic drug initiation. This carries defi-
nite advantages in lowering cohort size and cost, but the
exceptionally high cumulative TD incidence in that spe-
cies, reaching 100% in one report [72], raises some con-
cerns about the immediate applicability of the marmoset
model to human TD. Other strategies could eventually
be developed to increase TD susceptibility in monkeys,
with the aim to dampen neuroadaptive mechanisms
[49], or inversely, to amplify abnormal molecular signal-
ling triggered by antipsychotic drugs [89-92].
Neuropathological examination of baboons with TD
following exposure to the dehydrated product of halo-
peridol revealed no obvious changes in neuronal density
and neuropeptide content (substance P, enkephalin) in
the basal ganglia relative to control animals, but gliosis
in the caudate nucleus was observed in the TD group
[64]. A 25% reduction in density of the magnocellular
cholinergic neurons was found in the anterior portion of
the nucleus basalis of Meynert in the TD brains only,
while the striatal cholinergic interneurons were spared.
The functional impact of this loss on the activity of the
cortico-subcortical circuits, and on the subthalamic
nucleus in particular, remains undetermined. The regio-
nal reductions in glutamate decarboxylase (GAD) activ-
ity found initially in the substantia nigra only in
capuchins with severe TD left untreated for 2 months
before sacrifice, affecting to a lesser extent the medial
globus pallidus and subthalamic nucleus [80,70], were
not consistently replicated in subsequent studies [91]. A
single 2-deoxyglucose study involving 4 capuchins with
chronic TD left untreated for 4 months showed
decreased uptake levels in the medial globus pallidus
and ventral (VA/VL) thalamus compared to 3 controls,
suggesting parallel changes in synaptic activity within
the inputs to these structures susceptible to promote
dyskinesia [92].
In conclusion, the animal models of TD discussed are
complementary and offer different ways to examine var-
ious aspects of antipsychotic drug responses. The
latency of onset, individual susceptibility, phenomenolo-
gic expression of the purposeless movements, and
Figure 2 Mean (± SD) tardive dyskinesia scores obtained in 6
animals rated on 3 different occasions 4 weeks apart. Individual
scores represent the sum of several body parts. The mean
coefficient of variation calculated from this data set with normal
distribution is 31.5%.
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non-human primate TD model convincingly similar to
the human condition, and best suited to address thera-
peutic issues. In our view, this model will continue to
contribute to our understanding of TD.
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Additional material
Additional file 1: Table S1. Experience of chronic antipsychotic drug
exposure in non-human primates [53-56,58,62-65,80,83-92].
Additional file 2: Segment #1 shows typical haloperidol-induced
vacuous chewing movements in a wild type mouse. Occasional, brief
vertical jaw movements are observed. The next segments show six
different capuchin monkeys still exposed to a maintenance intramuscular
weekly dose of antipsychotic drug when the videoclips were captured.
The phenomenology of the purposeless movements includes variable
orofacial, axial, and foot dyskinesias, at times admixed with mild dystonic
features. The animals are otherwise in good condition and able to feed,
groom, ambulate, and interact with peers.
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